Truist Financial’s Adial Pharmaceuticals ADIL Stock Holding History

Truist Financial’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-54	Closed	-$7.05K	–	2576
2023 Q2	$7.05K	Hold	54	–	–	﹤0.01%	2556
2023 Q1	$11.9K	Hold	54	–	–	﹤0.01%	2555
2022 Q4	$7.28K	Hold	54	–	–	﹤0.01%	2546
2022 Q3	$12K	Hold	54	–	–	﹤0.01%	2496
2022 Q2	$45K	Buy	+54	New	+$48.9K	﹤0.01%	2584

Other funds holding ADIL

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AWM

Abound Wealth Management Franklin, Tennessee $504M AUM 23.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Truist Financial's ADIL Position: Q3 2023 in Review

Truist Financial sold out of Adial Pharmaceuticals (ADIL) in Q3 2023, closing a stake of 54 shares — an estimated $7.05K sold.

Truist Financial first reported a position in ADIL in Q2 2022 and held it in 5 quarters. The position peaked at $45K in Q2 2022. 8 funds tracked by Wall St. Rank hold ADIL as of Q3 2023.

Truist Financial reported no remaining Adial Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Truist Financial sold 54 Adial Pharmaceuticals shares in Q3 2023, an estimated $7.05K.
Truist Financial first reported a position in Adial Pharmaceuticals in Q2 2022 and held it in 5 quarters.
Truist Financial's Adial Pharmaceuticals position peaked at $45K in Q2 2022.
8 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q3 2023.

Based on Truist Financial's 13F filing for Q3 2023, filed 14 Nov 2023.